Patch testing in Malaysia finds contact dermatitis drivers in chronic hand eczema—nickel and fragrance allergy lead, while cosmetics raise polysensitization risk.
|Articles|February 11, 2015
Segment 7: Comparing Known Adverse Events of HCV Drugs
A recent report from Adverse Events suggests that based on the pre-approval adverse events listed for Viekira Pak that Harvoni and Sovaldi may be safer, according to Keith Hoffman, Phd.
Advertisement
A recent report from Adverse Events suggests that based on the pre-approval adverse events listed for Viekira Pak that Harvoni and Sovaldi may be safer, according to Keith Hoffman, Phd.
However, the company plans to monitor what happens post-marketing with all 3 drugs to determine their true safety profiles. He added that Express Scripts’ adherence guarantee for Viekira Pak is encouraging because that is one of the concerns of choosing Viekira Pak over Harvoni.
“I think there’s going to be some interesting post-marketing adverse events that will cause separation in some of these drugs,” Dr Hoffman added.
Advertisement
Related to this article
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
The article explores the use of dose-intensive IV iron replacement to achieve long-term hemoglobin stability in patients with moderate to severe HHT-related bleeding. The approach recognizes what the author calls "the relentless and recurrent nature of HHT-associated bleeding," and may help patients achieve better quality of life.
Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.
OCT patterns help distinguish MS, NMOSD, and MOGAD after optic neuritis, while timing and protocol shape MRI's diagnostic yield, experts say.
Among people with HIV, lung cancer screening eligibility rose from 6% to 15% in 6 years, but uptake stayed under 30%.
Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.
CMS finalized the mandatory GLOBE Model, tying Part B drug rebates to international prices in areas covering 25% of beneficiaries from Jan. 1, 2027.
Advertisement
Advertisement
Trending on AJMC
1
CMS Finalizes Mandatory GLOBE Model to Test Lower Part B Drug Costs
2
Dual Agonist Survodutide Delivers Up to 13.1% Weight Loss in T2D
3
Lung Cancer Screening Lags for People With HIV as Eligibility Triples
4
VYD2311 Shows Superior Safety vs mRNA COVID-19 Vaccine
5